Literature DB >> 19891219

Advantages and limits of real-time epidemiological surveillance during military deployments: the experience of the French Armed Forces.

Jean-baptiste Meynard1, Hervé Chaudet, Gaetan Texier, Bruce Dupuy, Benjamin Queyriaux, Liliane Pellegrin, Xavier Deparis, René Migliani, André Spiegel, Jean-Paul Boutin.   

Abstract

To perform epidemiological surveillance during deployments, the French military health service has developed a real-time surveillance approach. The objective was to identify the benefits and problems of this approach. A prototype of real-time surveillance has been set up in French Guiana since 2004. Its permanent evaluation has allowed identifying strengths and weaknesses. The experience has permitted expansion of the concept to French forces in Djibouti and also development of a global approach for the whole French armed forces. Real-time surveillance has shown its usefulness for early warning during different real and simulated situations. Functional and architectural choices have permitted interoperability with allied nations. However, the information produced was only the first step of the diagnostic epidemiological situation followed by other investigations. This first step of development has highlighted the required complementarity with traditional epidemiological surveillance.

Mesh:

Year:  2009        PMID: 19891219     DOI: 10.7205/milmed-d-04-7408

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  2 in total

1.  International society for disease surveillance conference 2011: building the future of public health surveillance.

Authors:  Daniel B Neill; Karl A Soetebier
Journal:  Emerg Health Threats J       Date:  2011-12-06

2.  Early trends in ECMO mortality during the first quarters of 2019 and 2020: Could we have predicted the onset of the pandemic?

Authors:  J W Awori Hayanga; Jahnavi Kakuturu; Alper Toker; Fatima Asad; Anthony Siler; Heather Hayanga; Vinay Badhwar
Journal:  Perfusion       Date:  2022-07-15       Impact factor: 1.581

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.